|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||5.72 - 5.96|
|52 Week Range||4.26 - 6.45|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||16.31|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
REHOVOT, Israel, Sept. 25, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor ...
Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention. The Company is collaborating with Massachusetts General Hospital (MGH) which is conducting and funding a study being led by James F. Markmann, M.D., Ph.D., Chief, Division of Transplant Surgery, MGH, who is the Claude E. Welch Professor of Surgery at Harvard Medical School.
Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that, as a result of the recently settled labor strike at its Beit Kama production facility in Israel, part of its 2018 planned product shipments are likely to be delayed and supplied in early 2019. As a result, the Company is revising its full-year 2018 revenue guidance from the previously provided range of $116 million to $120 million to a range of $102 million to $108 million.
Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.
Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employee’s Committee”), the Histadrut - General Federation of Labor in Israel (the “Histadrut”), and a Mediator appointed by the parties, signed a binding Memorandum of Understanding (the “Binding MoU”) that terminates the previously disclosed labor strike.
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.
Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...
Total Revenues for Second Quarter were $33.8 Million, a 4% Increase Over Second Quarter of 2017 Total Revenues for First Half of 2018 were $51.3 Million, a 16% Increase Over First Half of 2017 Gross Profit ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern Time. To listen ...
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter and six months ended June 30, 2018, prior to the open of the U.S. financial markets on Tuesday, August 7, 2018. Kamada management will host an investment community conference call on Tuesday, August 7 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-263-0877 (from within the U.S.), 1809 212 883 (from Israel), or 646-828-8143 (International) and entering the conference identification number: 4166824.
The U.S. medical device industry has exhibited strong and sustainable growth of late due to an aging population and increasing incidences of chronic and lifestyle diseases. Elimination of the tax will result in huge savings for the medical device players, in turn compelling them to focus on innovation. Per consulting specialist Emergo, the U.S. medical device industry was valued at $147.7 billion in 2016 and is projected to grow significantly through 2019 to $173 billion.
On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time. To listen to ...
Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.
In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.
Engineers in both the energy and biotech sectors are among top earners, surpassing Wall Street. Yahoo Finance's Seana Smith, Jennifer Rogers and Pras Subramanian discuss.